Evidence map›Paper›PMID 42202221›Full record

ReviewJournal of Huntington's disease2026

Clinical implications of loss of interruption variants for diagnosis, genetic counselling, and clinical trials in Huntington's disease.

Hailey Findlay Black, Jessica Levesley, Chris Kay, Stephanie Bortnick, Kyla Javier, Michael R Hayden

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of Huntington's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hailey Findlay BlackCentre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, Canada.ORCID 0000-0003-2479-2463
Jessica LevesleyCentre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, Canada.ORCID 0000-0002-8773-4634
Chris KayCentre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, Canada.ORCID 0000-0002-8170-4805
Stephanie BortnickCentre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, Canada.
Kyla JavierCentre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, Canada.ORCID 0009-0006-7514-4684
Michael R HaydenCentre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, Canada.ORCID 0000-0001-5159-1419

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Age of onset in Huntington disease (HD) is influenced by

Indexed as

Clinical Trials as TopicGenetic CounselingHuntingtin ProteinHuntington DiseaseTrinucleotide RepeatsGenetic VariationHumansPenetranceHTT protein, humanHuntingtin Proteinclinical trialgenetic counsellinggenetic modifiergenetic testinggenetic variantHuntington diseaseHuntington's diseaseintermediate alleleloss of interruptionreduced penetrance

Identifiers

PMID42202221
PMCPMC13400817

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.